CELLforCURE (SEQENS)
Les Ulis, FR
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
80.3
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
✓ EMA GMP (4)
○ MHRA GMP
Quick Facts: CELLforCURE (SEQENS)
- Signal Score
- 80.3/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Les Ulis, FR
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About CELLforCURE (SEQENS)
French cell therapy CDMO, part of SEQENS group.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
CELLforCURE (SEQENS) EMA GMP Compliance 4 certificates
2022-06
2022-06
2022-06
2022-06
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| 2022_HPF_FR_173_IV_P_2025 | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_174_IV_P_2025 | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_173_IV | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_174_IV | Cellforcure | France | 2022-06-10 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Oct 07, 2026
Frequently Asked Questions About CELLforCURE (SEQENS)
Does CELLforCURE (SEQENS) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA GMP certificates for CELLforCURE (SEQENS).
What is CELLforCURE (SEQENS)'s CDMO Signal Score?
CELLforCURE (SEQENS) has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating CELLforCURE (SEQENS) for a manufacturing program?
Use the free AI matchmaker to compare CELLforCURE (SEQENS) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 91.1
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.9
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.3
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody